Results of a 2-Arm, Phase 2 Clinical Trial Using Post-Transplantation Cyclophosphamide for the Prevention of Graft-Versus-Host Disease in Haploidentical Donor and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation

BACKGROUND: High-dose, post-transplantation cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD) has improved outcomes in haploidentical (HAPLO) stem cell transplantation (SCT). However, it remains unclear whether this strategy is effective in SCT from 1-antigen human leukocyte antige...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer
Asıl Yazarlar: Gaballa, Sameh, Ge, Isabell, Fakih, Riad El, Brammer, Jonathan E., Kongtim, Piyanuch, Tomuleasa, Ciprian, Wang, Sa A., Lee, Dean, Petropoulos, Demetrios, Cao, Kai, Rondon, Gabriela, Chen, Julianne, Hammerstrom, Aimee, Lombardi, Lindsey, Alatrash, Gheath, Korbling, Martin, Oran, Betul, Kebriaei, Partow, Ahmed, Sairah, Shah, Nina, Rezvani, Katayoun, Marin, David, Bashir, Qaiser, Alousi, Amin, Nieto, Yago, Qazilbash, Muzaffar, Hosing, Chitra, Popat, Uday, Shpall, Elizabeth J., Khouri, Issa, Champlin, Richard E., Ciurea, Stefan O.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5459484/
https://ncbi.nlm.nih.gov/pubmed/27404668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30180
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller